FOAMIX PHARMACEUTICALS LTD's ticker is FOMX and the CUSIP is M46135105. A total of 56 filers reported holding FOAMIX PHARMACEUTICALS LTD in Q2 2016. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2018 | $3,000,000 | -0.7% | 598,792 | +1.7% | 0.10% | -5.6% |
| Q1 2018 | $3,020,000 | -8.3% | 588,760 | +7.4% | 0.11% | -14.4% |
| Q4 2017 | $3,294,000 | +11.7% | 548,042 | +3.1% | 0.12% | +8.7% |
| Q3 2017 | $2,950,000 | +24.8% | 531,567 | +4.3% | 0.12% | +32.2% |
| Q2 2017 | $2,364,000 | +10.5% | 509,535 | +17.8% | 0.09% | +19.2% |
| Q1 2017 | $2,140,000 | -75.9% | 432,398 | -45.9% | 0.07% | -76.7% |
| Q4 2016 | $8,864,000 | +21.2% | 798,591 | +1.1% | 0.31% | +26.7% |
| Q3 2016 | $7,316,000 | +87.9% | 790,116 | +28.8% | 0.25% | +77.7% |
| Q2 2016 | $3,894,000 | -3.4% | 613,236 | -0.8% | 0.14% | +6.1% |
| Q1 2016 | $4,030,000 | -22.4% | 618,107 | -3.5% | 0.13% | -25.1% |
| Q4 2015 | $5,193,000 | +29.1% | 640,378 | +16.7% | 0.18% | +20.7% |
| Q3 2015 | $4,022,000 | +3.9% | 548,724 | +45.3% | 0.14% | +8.2% |
| Q2 2015 | $3,871,000 | +30.5% | 377,616 | +17.7% | 0.13% | +30.1% |
| Q1 2015 | $2,967,000 | +98.1% | 320,742 | +50.1% | 0.10% | +71.7% |
| Q4 2014 | $1,498,000 | – | 213,680 | – | 0.06% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| GREAT POINT PARTNERS LLC | 4,781,708 | $28,738,000 | 4.90% |
| DSC Advisors, L.P. | 1,187,604 | $7,138,000 | 4.14% |
| Opaleye Management Inc. | 960,000 | $5,769,000 | 1.85% |
| DAFNA Capital Management LLC | 352,741 | $2,120,000 | 1.14% |
| Vivo Capital, LLC | 855,000 | $5,139,000 | 1.10% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 382,838 | $2,301,000 | 0.81% |
| SENZAR ASSET MANAGEMENT, LLC | 377,397 | $2,268,000 | 0.58% |
| Sio Capital Management, LLC | 131,200 | $789,000 | 0.44% |
| Perceptive Advisors | 1,117,324 | $6,715,000 | 0.22% |
| Tekla Capital Management LLC | 930,398 | $5,592,000 | 0.22% |